BioMarin announces stable and durable annualized bleed control in the largest phase 3 gene therapy study in adults with severe Haemophilia A.
Orchard Therapeutics announces historic agreement making Libmeldy available by NHS England for MLD patients.
UCLB spinout, Senceive, is acquired by Eddyfi/NDT.
Series A funding to rapidly advance cutting-edge science.
Axovia Therapeutics, backed by Deerfield Management Co., launched to develop transformative medicines for ciliopathies.
Achilles Therapeutics announces its IPO on NASDAQ.
NovalGen doses its first patient in Phase I study in Chronic Lymphocytic Leukaemia and Mantle Cell Lymphoma.
from Syncona in their Series C funding round, to develop curative gene therapies for chronic systemic diseases.
UCLB and Apollo Therapeutics secure first out-licensing deal to Deerfield, a leading U.S. healthcare investment firm.
Humanloop raises funding to teach AI to learn from humans faster.
UCLB launches funding for early-stage social ventures.
Series A financing, backed by Syncona.
NHS England provides online support, developed at UCL, for Type 2 diabetes.
to address the 'grey zone' of heart disease treatment.
in oversubscribed Series B financing round.
of funding for spinout, AstronauTx for dementia research.
Dr Anne Lane appointed as new Managing Director for UCLB.
Four UCLB spinout companies are named finalists in the European Lifestars Awards: Ixico, Orchard Therapeutics, Quell Therapeutics, Autolus Therapeutics.
Development of a new gene therapy for the treatment of Haemophilia A by Prof. Amit Nathwani, UCL Cancer Institute licensed to BioMarin, is on track.
Series B funding to drive its programmes through clinical development.
Series C financing to advance gene therapy pipeline.
Series A financing to progress liver disease and pancreatic cancer treatment.
UCLB spinout, Endomag wins two prestigious awards: The Queen's Award for Enterprise in Innovation, Institute of Physics' British Business Innovation Award.
Series C funding to establish better breast cancer care.
Orchard Therapeutics win GUV Deal of the Year Award, for its oversubscribed $110million Series B funding round.
BioMarin provides 1.5 years of clinical data for Valoctocogene Roxaparvovec gene therapy for severe Haemophilia A, developed by Prof. Amit Nathwani, UCL Cancer Institute.
First patient treated in trial of a novel liver dialysis device, DIALIVE.
Apollo Therapeutics launches its first four drug discovery programmes in collaboration with academics at all three partner universities, spanning a variety of disease areas and drug modalities.
Series B financing to advance transformative gene therapy pipeline.
Series C funding to establish clinical Proof of Concept for three novel haemotological cancer programmes.
£50m UCL Technology Fund launched to support academics whose research has commercial potential.
£40m Apollo Therapeutics Fund launched to drive therapeutic innovation.
Research into a potential cure for blindness.
BioMarin provides positive data from its phase 1/2 clinical trial, showing that patients with Haemophilia A had improved and sustained clotting function.
Series A investment to deliver new treatments for liver disease.
Series B funding to help early detection of ovarian cancer.
BioMarin enrols first patient in phase 1/2 trial of gene therapy drug for the treatment of Haemophilia A.
UCLB and Cycle Pharmaceuticals enter into partnership to repurpose drugs for liver diseases.
UCL rated top UK university by research strength in the REF2014.
Helicon Health and Inhealthcare join forces to improve stroke prevention.
in Series A financing round, backed by Syncona and UCLB, for the development of cancer immunotherapies.
UCL professors working with UCLB develop a stem cell transplantation therapy which could restore sight to the blind.
Avatar therapy helps silence voices in schizophrenia.
Puridify is founded, providing purification solutions for biotherapeutic manufacturing.
Canbex Therapeutics commences phase I clinical trial of lead product for the potential treatment of spasticity in multiple sclerosis.
private placement, to continue their treatment of Hepatic Encephalopathy.
financing round, for the treatment of spasticity in multiple sclerosis.